| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... New England Journal of Medicine 370 (3), 211-221, 2014 | 1563 | 2014 |
| Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors KA Schalper, M Carleton, M Zhou, T Chen, Y Feng, SP Huang, AM Walsh, ... Nature medicine 26 (5), 688-692, 2020 | 347 | 2020 |
| Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection GT Everson, KD Sims, M Rodriguez-Torres, C Hézode, E Lawitz, ... Gastroenterology 146 (2), 420-429, 2014 | 271* | 2014 |
| Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder V Coric, HH Feldman, DA Oren, A Shekhar, J Pultz, RC Dockens, X Wu, ... Depression and anxiety 27 (5), 417-425, 2010 | 196 | 2010 |
| Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders AS Lok, DF Gardiner, C Hézode, EJ Lawitz, M Bourlière, GT Everson, ... Journal of hepatology 60 (3), 490-499, 2014 | 171 | 2014 |
| Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1–infected subjects RE Nettles, D Schürmann, L Zhu, M Stonier, SP Huang, I Chang, C Chien, ... The Journal of infectious diseases 206 (7), 1002-1011, 2012 | 118 | 2012 |
| The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no … GJ de Grooth, KE Zerba, SP Huang, Z Tsuchihashi, T Kirchgessner, ... Journal of the American College of Cardiology 43 (5), 854-857, 2004 | 101 | 2004 |
| 1422 Potent Viral Suppression with all-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (NS5B Inhibitor),+/− ribavirin, in treatment-naive patients with chronic HCV … M Sulkowski, D Gardiner, E Lawitz, F Hinestrosa, D Nelson, P Thuluvath, ... Journal of Hepatology, S560, 2012 | 97 | 2012 |
| Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile … G Tong, JS Wang, O Sverdlov, SP Huang, R Slemmon, R Croop, ... Clinical therapeutics 34 (3), 654-667, 2012 | 91 | 2012 |
| High Rate of Sustained Virologic Response with the All-Oral Combination of Daclatasvir (NS5A Inhibitor) Plus Sofosbuvir (Nucleotide NS5B Inhibitor), With or Without Ribavirin … MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... Hepatology 56 (6), 1516A-1517A, 2012 | 88 | 2012 |
| Pharmacodynamics of selective inhibition of γ-secretase by avagacestat CF Albright, RC Dockens, JE Meredith, RE Olson, R Slemmon, KA Lentz, ... Journal of Pharmacology and Experimental Therapeutics 344 (3), 686-695, 2013 | 77 | 2013 |
| Sustained virologic response with daclatasvir plus sofosbuvir+/-ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or … MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, ... JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 28, 155-155, 2013 | 68 | 2013 |
| Single-and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C C Pasquinelli, F McPhee, T Eley, C Villegas, K Sandy, P Sheridan, ... Antimicrobial agents and chemotherapy 56 (4), 1838-1844, 2012 | 66 | 2012 |
| A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects R Dockens, JS Wang, L Castaneda, O Sverdlov, SP Huang, R Slemmon, ... Clinical pharmacokinetics 51, 681-693, 2012 | 53 | 2012 |
| Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis AK Goodenough, JM Onorato, Z Ouyang, S Chang, AD Rodrigues, ... Chemical research in toxicology 24 (9), 1575-1585, 2011 | 53 | 2011 |
| Sustained Virologic Response in Chronic HCV Genotype (GT) 1-Infected Null Responders With Combination of Daclatasvir (DCV; NS5A Inhibitor) and Asunaprevir (ASV; NS3 Inhibitor … AS Lok, DF Gardiner, C Hezode, E Lawitz, M Bourliere, GT Everson, ... Hepatology 56, 230A-231A, 2012 | 52 | 2012 |
| An Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naïve Patients with Genotype (GT) 1 … GT Everson, KD Sims, M Rodriguez-Torres, C Hezode, E Lawitz, ... Hepatology 56 (6), 1517A-1518A, 2012 | 50 | 2012 |
| An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples JD Hulmes, D Bethea, K Ho, SP Huang, DL Ricci, GJ Opiteck, SA Hefta Clinical proteomics 1, 17-31, 2004 | 50 | 2004 |
| Organic anion transporting polypeptide‐mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease T Eley, YH Han, SP Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, ... Clinical Pharmacology & Therapeutics 97 (2), 159-166, 2015 | 46 | 2015 |
| Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men G Tong, L Castaneda, JS Wang, O Sverdlov, SP Huang, R Slemmon, ... Clinical drug investigation 32, 761-769, 2012 | 46 | 2012 |
Mark S. Sulkowski, MDProfessor of Medicine; Johns Hopkins University School of MedicineVerified email at jhmi.edu
